Company and Stock Identity

How Roche Connects to the Public Market

Company structure
Public company
Market access
Direct listing: SIX Swiss Exchange: RO.
Stock name
F. Hoffmann-La Roche Ltd
Ticker and exchange
SIX Swiss Exchange: RO
Research focus
This group asks one question about every partnership: how far did the work actually go. Roche is at the start with Chai Discovery. The announcement names no disease area, no money and no timetable, so treat it as access to a design tool rather than a programme with a result. The useful check is whether Roche says anything about it in its own media releases, because a partner announcement is the partner's choice of words. Roche also runs a large diagnostics business, so when you meet a Roche AI claim, work out first whether it belongs to the drug side or the diagnostics side. Those two are judged by different buyers on different proof.

Roche says it this way on its own share and bond page, read on 2026-11-07: "Roche's bearer shares (ticker symbol: RO) and participation certificates (ticker symbol: ROP) are listed on SIX Swiss Exchange." The same page gives ISIN CH0012032113 for the bearer shares and CH1499059983 for the participation certificates, and says "Roche's ADR trades on the OTCQX International Premier under the ticker symbol RHHBY" with CUSIP 771195104. The Swiss exchange's own share page carries that first ISIN under the security name ROCHE I. One honest gap: the only legal entity name printed on any Roche corporate page this desk could read is F. Hoffmann-La Roche Ltd, so that is the name this record carries, and no Roche page read on 2026-11-07 named the group holding company. No change of control was found. Because the ADR sits on OTCQX rather than Nasdaq or the New York Stock Exchange, this record carries no quote symbol and the site shows no price for it.

A current price is not available in the automated United States market snapshot. Use the named exchange or the company investor-relations page for current trading data.

Open the public company market data feed for the full directory, ownership relationships, stock identifiers, and dated snapshots.

First-Hand Company News

Latest Developments

... Chai Discovery ... Company source

Roche will use Chai Discovery AI models in several of its own drug programmes

Chai Discovery said on 5 November 2026 that it had agreed a collaboration with Roche to build its AI models into multiple Roche drug discovery programmes. Chai Discovery co-founder and chief executive Joshua Meier is quoted saying the work "expands the range of therapeutic programs that can benefit from AI-driven molecular design," and Roche head of corporate business development Boris L. Zaitra is quoted saying the platform fits Roche research strategy. The announcement points at a model it calls Chai-3 and says it performs strongly on hard targets. It names no disease area, no payment, no milestone and no timetable, discloses no financial terms, and states no regulatory status for anything.

Why it matters: Roche is one of the biggest buyers in this market, so its name on a licence is a signal about how seriously large research organisations now take AI molecule design. For an investor, the more telling fact is the pattern: Chai Discovery has now announced its own agreements with a run of large drug companies inside a single year, which looks less like one lucky deal and more like a product people keep buying. Two limits though. Multiple programmes is not the same as one approved drug, and nothing here says a molecule designed this way has worked in an animal, let alone a person. And because no terms were disclosed, there is no way to tell a large committed contract from a small evaluation licence. The result worth waiting for is a Roche programme that names a Chai-designed molecule and reports data on it.

See company developments across the healthcare AI market.

Careers and Qualifications

What to Know Before Applying

Work areas: The global careers site says Roche has more than 103,000 employees worldwide. The areas it puts forward are information technology, naming software developers, data analysts and IT experts, procurement, and a shared services group it calls Roche Services and Solutions. The openings it highlights sit in Germany, Austria and Switzerland alongside global roles. It also publishes two internal survey numbers from 2025: 81 percent of employees say they are happy to work at Roche and 87 percent say their work has a positive impact on society.

Qualification signal: A company this size hires people to build the system around a tool, not the tool. For the AI work, the experience that counts is getting software accepted for use by a regulated research or diagnostics team, with a named owner and an audit trail behind it. Building a clever model on your own counts for less. Ask which business a role sits in before you take it, because drug research, diagnostics and shared services can all advertise the same job title and mean three different jobs.

Check current roles at Roche. A careers page is the source of record for openings. This profile does not claim a role is open unless the company lists it now.

Related Healthcare AI Roles

Training to Compare

Buyer Snapshot

Best-fit buyer
Research and development leaders, clinical development teams, business development staff, and investors tracking where AI partnerships lead
Primary use case
Sponsor, license, or partner on AI research, molecule design, and trial measurement in drug development
Typical deployment
Drug developer. AI arrives through a research collaboration, a licence, or a tool used inside a clinical trial.

Evidence questions

  • What stage did the agreement reach, and were any payments or milestones disclosed?
  • Which programs or molecules does the AI work actually touch?
  • Has anything from the collaboration reached a clinical endpoint rather than a press release?

Regulatory and workflow questions

  • If AI produced a measurement used in a trial, has a regulator accepted that measurement?
  • Which regulatory submissions, if any, depend on the AI work?
  • Who is responsible for the quality of an AI-generated result inside a trial record?

Data and contract questions

  • Whose data trained the model, and what did the drug company contribute?
  • Who owns a molecule or design the collaboration produces?
  • What happens to the shared data if the collaboration ends?

Evidence and Regulation

FDA Clearances on Record

No clearance is linked in this directory. That is not automatically a mark against the company. Some products support the people doing the work instead of reading a patient image or signal themselves.

First-Hand Sources